Dyslipidemia Drug Market Analysis and 2033 CAGR Japan Updates

Dyslipidemia Market Size reached US$ 16.03 Billion in 2024 and is expected to reach US$ 40.33 Billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033.

Latest Japan News
Health Supplement Alert in Japan

Red yeast rice supplements (used to lower cholesterol) sold by Kobayashi Pharmaceutical have been linked to two deaths and over 100 hospitalizations.

Triggering emergency inspections and recalls for cholesterol-lowering products in Japan

Unlock exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://datamintelligence.com/download-sample/dyslipidemia-market?kb

Dyslipidemia Market Overview

Dyslipidemia is a condition by abnormal blood lipid levels elevated LDL ("bad") cholesterol and triglycerides, and/or low HDL ("good") cholesterol-which raises the risk of atherosclerosis and cardiovascular diseases

Research Methodology:

The global Dyslipidemia Market research report is based on a combination of primary and secondary data sources. The study carefully analyzes various factors influencing the industry, including government regulations, market dynamics, competitive landscape, historical trends, current conditions, and technological progress. It also evaluates future developments, related industry trends, market volatility, growth prospects, potential obstacles, and emerging challenges.

Segment Covered in the Dyslipidemia Market:

By Treatment Type: Statins, Bile Acid Sequestrants, PCSK9 Inhibitors, siRNA Therapy, Cholesterol Absorption Inhibitors, Fibrates, Niacins, Omega-3 Fatty Acid Derivatives, Others

By Route of Administration: Oral, Parenteral

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/dyslipidemia-market?kb

List of the Key Players in the Dyslipidemia Market:

Viatris Inc., AstraZeneca, Organon group of companies, Regeneron Pharmaceuticals, Inc., Amgen Inc., Novartis AG, Esperion Therapeutics, Inc., Pfizer Inc., Teva Pharmaceuticals USA, Inc., Lupin Pharmaceuticals, Inc. and among others.

Emerging Players

The emerging players in the dyslipidemia market include Arrowhead Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., Gemphire Therapeutics Inc. and Ionis Pharmaceuticals, Inc. among others.

Industry Development:

Recent Developments in Hyperlipidemia Treatment
February 2025 - LIB Therapeutics Inc.: LIB Therapeutics announced that the U.S. FDA has accepted the Biologics License Application (BLA) for Lerodalcibep, a novel treatment aimed at lowering LDL-C levels. It is intended for patients with atherosclerotic cardiovascular disease (ASCVD), individuals at high or very high risk of ASCVD, and those with primary hyperlipidemia, including heterozygous and homozygous familial hypercholesterolemia (HeFH/HoFH) aged 10 years and older.

June 2024 - Daewoong Bio: Daewoong Bio introduced a combination therapy featuring rosuvastatin and Omega-3. This new product is designed to enhance lipid profile management, offering better stability and tolerance compared to rosuvastatin monotherapy.

March 2024 - Esperion Therapeutics: Esperion announced that the FDA has approved expanded labeling for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid + ezetimibe). The updated labels now include cardiovascular risk reduction and LDL-C lowering for both primary and secondary prevention, with usage approved as monotherapy or in combination with statins, based on strong CLEAR Outcomes trial results.

March 2024 - Regeneron Pharmaceuticals Inc.: The FDA approved an expanded indication for Praluent® (alirocumab) to include pediatric patients aged 8 years and older diagnosed with heterozygous familial hypercholesterolemia (HeFH). The treatment can be used alongside dietary modifications and other lipid-lowering therapies.

Regional Analysis for Dyslipidemia Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

The Report Includes:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Go-to-market Strategy.

➡ Neutral perspective on the market performance.

➡ Customized regional/country reports as per request and country level analysis.

➡ Potential & niche segments and regions exhibiting promising growth covered.

People Also Ask:

➠ What are the global sales, production, consumption, imports, and exports in the Dyslipidemia market?

➠ Who are the top manufacturers, and what are their capacity, production, sales, pricing, and revenue stats?

➠ What key opportunities and challenges do vendors face in the Dyslipidemia industry?

➠ Which product types, applications, or end-users are driving market growth, and what is their market share?

➠ What are the major growth drivers and restraints of the Dyslipidemia market?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.